Gabather

0.03 SEK

-7.30 %

Less than 1K followers

GABA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-7.30 %

-6.78 %

-13.16 %

-32.10 %

-69.03 %

-69.79 %

-97.30 %

-97.70 %

-99.22 %

Gabather is a pharmaceutical company whose business focus is to develop drug candidates for the treatment of neurological diseases. The focus is particularly on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.

Market cap

13.51M SEK

Turnover

44.1K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

15/12

2025

Extraordinary general meeting '25

26/2

2026

Annual report '25

29/5

2026

Interim report Q1'26

All

Press releases

3rd party

ShowingAll content types

Regulatory press releaseyesterday

Gabather AB: Gabather offentliggör utfall i utnyttjandet av teckningsoptioner av serie TO 7

Third party research12/1/2025, 1:57 PM

Gabather: Eager to start the TOTEMS study - VH Corp

* A TOTEMS study article published in Frontiers in Psychiatry * The exercise of TO 7 warrants provides some financial relief * We keep our fair value of SEK 0.092 per share Gabather's reported figures in its recent Q3 report were close to our estimates...

Press release12/1/2025, 1:45 PM

Västra Hamnen Market Focus: Gabather: Eager to start the TOTEMS study

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release11/28/2025, 9:35 AM

Gabather AB: Påminnelse: Lösenperiod för GABA TO7 snart slut

Regulatory press release11/27/2025, 7:30 AM

Gabather AB: Gabather publicerar delårsrapport 1 januari - 30 september 2025

Regulatory press release11/26/2025, 10:57 AM

Gabather AB: Gabather uppmärksammar den växande marknadspotentialen inom CIAS - en global möjlighet på 60-100 miljarder SEK

Regulatory press release11/24/2025, 7:30 AM

Gabather AB: Gabather lämnar in provisorisk patentansökan för ny terapeutisk plattform inom neurologi och psykiatri

Regulatory press release11/19/2025, 8:08 AM

Gabather AB: Gabather presenterar nya prekliniska och kliniska data som ytterligare bekräftar den kliniska potentialen för GT-002 vid Society for Neuroscience Annual Meeting, USA, 2025

Regulatory press release11/18/2025, 9:28 AM

Gabather AB: Gabather meddelar att inlösenperioden av teckningsoptioner av serie TO 7 har inletts och bjuder in till investerarpresentationer.

Regulatory press release11/17/2025, 9:29 PM

Gabather AB: Rättelse: Saknad MAR-etikett i tidigare pressmeddelande - Gabather har ingått garantiåtaganden avseende nyttjandet av teckningsoptioner av serie TO 7

Regulatory press release11/17/2025, 8:45 PM

Gabather AB: Gabather har ingått garantiåtaganden avseende nyttjandet av teckningsoptioner av serie TO 7

Regulatory press release11/14/2025, 9:20 PM

Gabather AB: Teckningskursen för utnyttjande av teckningsoptioner av serie TO 7 i Gabather har fastställts till 0,025 SEK per aktie inför teckningsperioden som inleds den 17 november 2025

Regulatory press release11/13/2025, 5:00 PM

Gabather AB: KALLELSE TILL EXTRA BOLAGSSTÄMMA I GABATHER AB (PUBL)

Regulatory press release11/6/2025, 11:01 AM

Gabather AB: Gabather har utsett valberedning inför årsstämman 2026

Regulatory press release11/3/2025, 9:30 PM

Gabather AB: Gabather upptar brygglån om 0,7 MSEK

Press release10/30/2025, 7:30 AM

Gabather AB: Gabather medförfattar granskad publikation om TOTEMS kliniska prövningsprotokoll accepterad i Frontiers in Psychiatry

Regulatory press release9/9/2025, 9:36 AM

Gabather AB: Gabathers CFO Kristofer Svensson lämnar sin tjänst

Third party research9/1/2025, 10:05 AM

Gabather: TOTEMS-study delayed, not derailed - VH Corp

* Issues with clinical test material delays TOTEMS-study * New chairman elected at the AGM * We keep our fair value of SEK 0.092 per share Before releasing its Q2 2025 report, Gabather announced that the TOTEMS-study would be delayed due to issues with...

Press release9/1/2025, 10:00 AM

Västra Hamnen Market Focus: Gabather: TOTEMS-study delayed, not derailed

Regulatory press release8/28/2025, 6:30 AM

Gabather AB: Gabather publicerar delårsrapport 1 januari - 30 juni 2025

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.